香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，本公司自主研發的伊匹木單抗生 物類似藥HLX13（重組抗CTLA-4全人單克隆抗體注射液）（「HLX13」）一綫治 療不可切除的晚期肝細胞癌(HCC)患者的1/3期臨床研究於中國境內完成首例 患者給藥。 B. 臨床試驗設計及目的 本研究為一項多中心、隨機、雙盲、平行對照1/3期臨床研究，旨在評估 HLX13與其原研藥YERVOY® （美國市售和歐盟市售）在既往未經治療的不可 切除的晚期肝細胞癌(HCC)患者中的藥代動力學(PK)特徵、有效性、安全性 和免疫原性相似性。合格的受試者將按2:1:1的比例隨機分配至三組 ...

Major Events - Heng Rui Medicine (01276) plans to globally issue 224.5 million H-shares, expected to be listed on May 23 [1] - MIRXES-B (02629) will conduct an IPO from May 15 to May 20, aiming to globally issue 46.62 million shares [1] - Green Tea Group (06831) received 317.54 times subscription for its public offering in Hong Kong, with a final issue price of HKD 7.19 per share [1] - CSPC Pharmaceutical Group (01093) signed an exclusive licensing agreement with Cipla for the commercialization of Irinotecan Liposome Injection in the United States [1] - CanSino Biologics (06185) received clinical trial approval for its inhaled tuberculosis booster vaccine in Indonesia [1] - Fuhong Hanlin (02696) has been included in the MSCI Global Small Cap Index [1] - Financial One Account (06638) received a privatization offer from Ping An Group (02318) at a premium of approximately 23.10% [1] Financial Reports - Alibaba-W (09988) reported revenue and net profit growth for the fiscal year 2025, with net profit attributable to shareholders increasing by 62% to CNY 129.47 billion [1] - NetEase-S (09999) announced Q1 results with net profit attributable to shareholders at CNY 10.301 billion, a year-on-year increase of 34.94%, and a quarterly dividend of USD 0.135 per share [1] - Geely Automobile (00175) released Q1 results showing a significant increase in profit attributable to shareholders of CNY 5.672 billion, up 263.59% year-on-year [1] - Beike-W (02423) reported a total transaction volume growth of 34.0% year-on-year in Q1, with net revenue increasing by 42.4% [1] - Minhua Holdings (01999) announced annual results with profit attributable to shareholders of HKD 2.063 billion, a decrease of 10.41% year-on-year [1] - Shoucheng Holdings (00697) reported Q1 results with profit attributable to shareholders of HKD 213 million, an increase of 80.5% year-on-year [1] - Fourth Paradigm (06682) showed strong performance in core business with total revenue of CNY 1.077 billion in Q1, a year-on-year growth of 30.1% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公司股東及潛在投資者在買賣本公司股份時務請審慎行事。 代表董事會 上海復宏漢霖生物技術股份有限公司 主席 Wenjie Zhang 香港，二零二五年五月十五日 於本公告日期，本公司董事會包括主席及非執行董事Wenjie Zhang先生，執行董 事朱俊博士，非執行董事陳啟宇先生、吳以芳先生、關曉暉女士、文德鏞先生及 Xingli Wang博士以及獨立非執行董事蘇德揚先生、陳力元博士、趙國屏博士及宋 瑞霖博士。 （股份代號：2696） 自願公告 本公司獲納入MSCI全球小型股指數成分股 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知本公 司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣布，近日，本公司獲納入MSCI全球小型 ...

Group 1 - The Hang Seng Index fell by 0.25%, down 59 points, closing at 23,581 points, while the Hang Seng Tech Index decreased by 0.62% [1] - Hong Kong's stock market saw a trading volume of HKD 110.1 billion in the morning session [1] Group 2 - BYD Co., Ltd. (01211) increased by 3.53%, with new energy vehicle sales in the first four months rising by 46.98% year-on-year, surpassing Toyota in Singapore [2] - NetEase-S (09999) rose by 1.8% ahead of its quarterly report release and an annual product exhibition next week [2] - Weimob Group (02013) surged by 20% following the establishment of an e-commerce product department by WeChat, indicating potential in AI development and WeChat small store business [2] - Tencent Music Entertainment Group (01698) rose over 7% post-earnings, with a steady increase in ARPPU and a 22.8% year-on-year growth in net profit for the first quarter [2] - Yixin Group (02858) saw an intraday increase of over 7%, with financing amounts facilitated by its fintech platform rising by 56.5% year-on-year in the first quarter [2] - China Tobacco Hong Kong (06055) increased by over 7%, signing a contract with Mengkun to boost its duty-free cigarette business, with potential for resource integration within the China Tobacco system [2] - Junshi Biosciences (02696) rose by over 6% after granting Sandoz AG rights for the development, production, and commercialization of product HLX13 [2] - Bruker Corporation (00325) saw a 6.48% increase in early trading, with a recent surge in new product launches indicating potential for high growth [2] - Dekang Agriculture and Animal Husbandry (02419) increased by over 11%, reporting sales revenue of HKD 1.867 billion from live pig sales in April, leading the industry in per-head profitability [2] - Xindong Company (02400) rose over 6% with the international launch of "Yise" scheduled for June, expected to further drive performance growth [2] - Beike-W (02423) fell by 4.14%, with a quarterly report set to be disclosed today, and institutions remain cautious about its profit outlook [2] Group 3 - MicroPort Scientific Corporation-B (02252) fell by 3.63% after announcing a discounted placement to raise funds, with the controlling shareholder cashing out nearly HKD 470 million [3]

（於中華人民共和國註冊成立的股份有限公司） Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （股份代號：2696） 於2025年5月8日（星期四）舉行的 股東周年大會 所提呈決議案之投票結果 上海復宏漢霖生物技術股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣 然宣佈於2025年5月8日（星期四）上午10時正假座中國上海市徐匯區宜州路188號 B8幢10樓會議室舉行的股東周年大會（「股東周年大會」）之投票結果。 茲提述本公司日期均為2025年4月15日之股東周年大會通告及通函（「通函」）。除 文義另有所指外，本公告所用詞彙與通函所界定者具有相同涵義。 股東周年大會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 於股東周年大會日期，本公司已發行股份（「股份」）總數為543,494,853股（包 含380,066,312股非上市股份及163,428,541股H股），該等股份持有人（或授權 代表） ...

Core Insights - Shanghai Junshi Biosciences Co., Ltd. (复宏汉霖) has successfully transitioned from a pre-profit biotech firm to a profitable entity, achieving a net profit of 546 million yuan in 2023 and a 50.3% year-on-year growth to 820 million yuan in 2024, marking it as the first company to achieve full profitability under the Hong Kong Stock Exchange's Chapter 18A for pre-profit biotech firms [1][3][6] Group 1: Business Strategy - The company has adopted a differentiated and global strategy, rapidly commercializing its innovative products and establishing a significant presence in the global market [1][3] - Junshi's innovative drug, Hanshu, has become the first and only product in the EU to potentially secure a market exclusivity period of up to 10 years [1][6] - The company has successfully launched four products in over 50 countries, reaching 750,000 patients by the end of 2024 [1][8] Group 2: R&D and Innovation - Junshi has focused on high-risk, differentiated indications for drug development, targeting less crowded markets such as small cell lung cancer and gastric cancer [5][6] - The company is advancing its PD-L1 targeted antibody-drug conjugate (ADC) project, HLX43, which is the second globally to enter clinical trials, exploring efficacy against five solid tumors [4][5] - AI technology is being utilized to shorten R&D timelines and reduce costs, with successful projects including the development of a second-generation hyaluronidase [7][8] Group 3: Global Expansion - Junshi has submitted 25 registration applications globally in 2024, receiving 17 approvals across various regions including China and the US [6][8] - The company has established a strong international presence, with a focus on markets in the US, EU, Japan, Southeast Asia, the Middle East, and Latin America [6][8] - Collaborations with global partners such as Abbott and Dr. Reddy's are being pursued to enhance early pipeline development and create a collaborative ecosystem [7][8]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [5]. Core Insights - The company has signed a collaboration and licensing agreement with Sandoz AG for the development and commercialization of its product HLX13, a recombinant anti-CTLA-4 monoclonal antibody, in several regions including the US and Europe, with potential payments up to $191 million [1]. - Sandoz, a leader in biosimilars, is expected to enhance the commercialization of HLX13, which is the first CTLA-4 monoclonal antibody biosimilar to enter Phase III clinical trials globally [2]. - The company has established a strong global presence through multiple licensing agreements for its biosimilars, generating significant upfront payments totaling $64 million in 2025 alone [3]. - The company plans to present clinical data for its innovative drugs HLX43 and HLX22 at the 2025 ASCO conference, with HLX43 expected to become a key product and HLX22 potentially changing the standard treatment for HER2-positive gastric cancer [4]. Financial Projections - The company is projected to achieve total revenues of 5.873 billion, 5.970 billion, and 7.125 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 2.60%, 1.64%, and 19.36% [5]. - The net profit attributable to shareholders is expected to be 827 million, 797 million, and 1.122 billion yuan for the same years [5].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [5]. Core Insights - The company has signed a collaboration and licensing agreement with Sandoz AG for the development and commercialization of its product HLX13, a recombinant anti-CTLA-4 monoclonal antibody, in several regions including the US and Europe, with potential payments up to $191 million [1]. - Sandoz, a leader in biosimilars, is expected to enhance the commercialization of HLX13, which is the first CTLA-4 monoclonal antibody biosimilar to enter Phase III clinical trials globally [2]. - The company has established a strong global presence through multiple licensing agreements for its biosimilars, generating significant upfront payments, showcasing its capabilities in overseas markets [3]. - The company plans to present clinical data for its innovative drugs HLX43 and HLX22 at the 2025 ASCO conference, with HLX43 expected to become a key product and HLX22 potentially changing the standard treatment for HER2-positive gastric cancer [4]. Financial Projections - The company is projected to achieve revenues of 5.873 billion, 5.970 billion, and 7.125 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 2.60%, 1.64%, and 19.36% [5]. - The net profit attributable to shareholders is expected to be 827 million, 797 million, and 1.122 billion yuan for the same years [5].

Performance Summary - Industrial and Commercial Bank of China (01398.HK) reported Q1 revenue of 204.688 billion yuan, a decrease of 2.61% year-on-year, and a net profit of 84.156 billion yuan, down 3.99% [3] - China Construction Bank (00939.HK) had Q1 operating income of 185.99 billion yuan, down 4.76% year-on-year, with a net profit of 83.351 billion yuan, also down 3.99% [3] - Agricultural Bank of China (01288.HK) achieved Q1 revenue of 186.735 billion yuan, an increase of 0.32% year-on-year, and a net profit of 71.931 billion yuan, up 2.2% [3] - Bank of China (03988.HK) reported Q1 revenue of 164.911 billion yuan, an increase of 2.41% year-on-year, but a net profit of 58.644 billion yuan, down 2.22% [3] - Postal Savings Bank of China (01658.HK) had Q1 revenue of 89.406 billion yuan, a slight decrease of 0.1%, and a net profit of 25.246 billion yuan, down 2.62% [3] - China Merchants Bank (03968.HK) reported Q1 revenue of 83.731 billion yuan, down 3.11% year-on-year, with a net profit of 37.286 billion yuan, down 2.08% [3] - Bank of Communications (03328.HK) had Q1 net operating income of 66.44 billion yuan, down 1.13%, but a net profit of 25.372 billion yuan, up 1.54% [3] - HSBC Holdings (00005.HK) reported Q1 revenue of 17.649 billion USD, down 14.95%, and a post-tax profit of 7.57 billion USD, down 30.15% [3] - China People's Insurance Group (01339.HK) achieved Q1 revenue of 156.589 billion yuan, up 12.8%, and a net profit of 12.849 billion yuan, up 43.4% [3] - China Life Insurance (02628.HK) reported Q1 revenue of 110.177 billion yuan, down 8.9%, but a net profit of 28.802 billion yuan, up 39.5% [3] - New China Life Insurance (01336.HK) had Q1 revenue of 33.402 billion yuan, up 26.1%, and a net profit of 5.882 billion yuan, up 19% [3] - China National Petroleum Corporation (00857.HK) reported Q1 revenue of 753.108 billion yuan, down 7.3%, but a net profit of 46.809 billion yuan, up 2.3% [3] - CNOOC (00883.HK) had Q1 revenue of 106.854 billion yuan, down 4.1%, and a net profit of 36.563 billion yuan, down 7.9% [3] - Huadian International Power (01071.HK) reported Q1 revenue of 26.577 billion yuan, down 14.14%, but a net profit of 1.93 billion yuan, up 3.66% [3] - China International Marine Containers (01880.HK) had Q1 revenue of 16.746 billion yuan, down 10.96%, and a net profit of 1.938 billion yuan, down 15.98% [3] - Air China (00753.HK) reported Q1 revenue of 40.023 billion yuan, down 0.11%, with a net loss of 2.044 billion yuan, an increase of 22.07% [3] - CITIC Securities (06030.HK) achieved Q1 revenue of 17.761 billion yuan, up 29.13%, and a net profit of 6.545 billion yuan, up 32% [3] - China Galaxy Securities (06881.HK) reported Q1 revenue of approximately 7.558 billion yuan, up 4.77%, and a net profit of approximately 3.016 billion yuan, up 84.86% [3] - CITIC Construction Investment Securities (06066.HK) had Q1 operating income of 4.919 billion yuan, up 14.54%, and a net profit of 1.843 billion yuan, up 50.07% [3] - Huatai Securities (06886.HK) reported Q1 revenue of approximately 8.232 billion yuan, up 34.83%, and a net profit of approximately 3.642 billion yuan, up 58.97% [3] - China Railway Construction (01186.HK) had Q1 revenue of 256.762 billion yuan, down 6.61%, and a net profit of 5.151 billion yuan, down 14.51% [3] - China Energy Engineering (03996.HK) reported Q1 revenue of 100.371 billion yuan, up 3.05%, and a net profit of 1.612 billion yuan, up 8.83% [3] - Times Electric (03898.HK) achieved Q1 revenue of 4.537 billion yuan, up 14.81%, and a net profit of 631 million yuan, up 13.42% [3] - Midea Group (00300.HK) reported Q1 revenue of 127.839 billion yuan, up 20.49%, and a net profit of 12.422 billion yuan, up 38.02% [3] - WH Group (00288.HK) had Q1 revenue of 6.554 billion USD, up 6.0%, and a profit of 364 million USD, up 20.9% [3] - Suncity Group (00880.HK) reported Q1 total revenue of 7.48 billion HKD, up 8.1%, and a net profit of 31 million HKD, turning profitable [3] - COSCO Shipping Ports (01199.HK) had Q1 revenue of 3.82 billion USD, up 14.7%, and a net profit of 839 million USD, up 33.5% [3] - Flat Glass Group (06865.HK) reported Q1 revenue of 4.079 billion yuan, down 28.76%, and a net profit of 106 million yuan, down 86.03% [3] - Zoomlion Heavy Industry (01157.HK) achieved Q1 revenue of 12.117 billion yuan, up 2.92%, and a net profit of 1.41 billion yuan, up 53.98% [3] - Ganfeng Lithium (01772.HK) reported Q1 revenue of approximately 3.772 billion yuan, down 25.43%, with a net loss of approximately 356 million yuan, narrowing by 18.93% [3] - Qingdao Port (06198.HK) had Q1 revenue of 4.807 billion yuan, up 8.51%, and a net profit of 1.402 billion yuan, up 6.51% [3] - China Shipbuilding Defense (00317.HK) reported Q1 revenue of approximately 3.641 billion yuan, up 29.73%, and a net profit of approximately 184 million yuan, up about 11 times [3] - Baiyunshan Pharmaceutical (00874.HK) had Q1 revenue of 22.473 billion yuan, down 2.06%, and a net profit of 1.821 billion yuan, down 6.99% [3] Investment Activities - New China Life Insurance (01336.HK) plans to invest no more than 10 billion yuan to subscribe to a private fund [4] - China Life Insurance (02628.HK) intends to invest 2 billion yuan to establish a partnership [4] Contract Signing - China Metallurgical Group (01618.HK) reported a new contract signing amount of 230.66 billion yuan in Q1, a decrease of 27.2% year-on-year, with overseas contracts amounting to 12.04 billion yuan, down 35.7% [5] Energy Production - Xin Tian Green Energy (00956.HK) completed power generation of 4.5442 million MWh in Q1, an increase of 10.37% year-on-year [6] - China Power (02380.HK) reported total electricity sales of 30.7477 million MWh in the first three months, up 2.59% year-on-year, with March sales of 10.9617 million MWh, up 3.95% [6] - Qingdao Port (06198.HK) achieved a total cargo throughput of 177 million tons in the first three months, up 2.9% year-on-year [6] Licensing Agreement - Fuhong Hanlin (02696.HK) entered into a licensing agreement with Sandoz AG for the commercialization of HLX13 in specified regions [6] Privatization Offer - Dingsheng Creation (00113.HK) received a privatization offer at a premium of approximately 50.63%, with a maximum cash consideration of about 1.0986 billion HKD [7] Share Buybacks - AIA Group (01299.HK) repurchased shares for 342.6 million HKD, buying back 6.2592 million shares at prices between 54.25 and 55.35 HKD [8] - J&T Express-W (01519.HK) repurchased shares for 9.2485 million HKD, buying back 1.54 million shares at prices between 5.98 and 6.03 HKD [8]

Core Viewpoint - The company has entered into a collaboration and licensing agreement with Sandoz AG for the development, production, and commercialization of its investigational product HLX13 in specified regions [1] Group 1: Agreement Details - The agreement grants Sandoz AG rights to develop, produce, and commercialize HLX13 in the United States, 42 European countries, Japan, Australia, and Canada [1] - Sandoz AG will pay up to $191 million to the company, which includes an upfront payment of $31 million and milestone payments related to development [1]